Skip to main content
. 2021 Nov 5;7(45):eabg1964. doi: 10.1126/sciadv.abg1964

Table 1. Clinical trial outcome.

NA, Not assessed.

Placebo l-Arginine P
Variable No. % No. %
Total number of evaluable patients 32 31
Radiological responses
  Complete 3 9.4 9 29 0.059 (C)
  Partial 4 12.5 15 48.4 <0.001 (C + P)
  Stable 11 34.4 4 13
  Progression 5 16 1 3.2
  NA 9 28.2 2 6.4
Symptomatic responses
  Complete 10 31.2 25 80.6
  Partial 6 18.8 4 13 0.002 (C + P)
  Stable 4 12.5 1 3.2
  Progression 12 37.5 1 3.2
  NA 0 0
Overall responses
  Complete 3 9.4 9 29 0.059 (C)
  Partial 4 12.5 15 48.4 <0.001 (C + P)
  Stable 11 34.4 4 13
  Progression 14 43.7 3 9.6